SREBF1 and metabolic dysfunction-associated steatotic liver disease: Interestingly XH is also able to attenuate lipogenesis in cultured hepatocytes and protect against NAFLD in mice and rats by suppressing the hepatic SREBP1 and diacylglycerol acyltransferase (DAG), activation of farnesoid X receptor (FXR), antagonizing PPARγ, and stimulating the Nrf2/RAGE/NF-κB axis [48,49,50,51].